Lipid-based amphotericin in pulmonary zygomycosis: Safety and efficacy of high exposure in a renal allograft recipient

Transplant Infectious Disease

Volumn 6, Issue 4, 2004, Pages 183-187

  Crompton, Jason A ^a,b   Alexander, D ^a   Somerville, T ^a   Shihab, F S ^a  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH HOSPITAL   (United States)

Author keywords

Amphotericin; Drug toxicity; Immunosuppression; Kidney failure; Kidney transplantation; Mycoses; Zygomycosis

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX;

ADULT; ARTICLE; CASE REPORT; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GRAFT PRESERVATION; HUMAN; KIDNEY ALLOGRAFT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LUNG MYCOSIS; MALE; MUCORMYCOSIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECIPIENT;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CREATININE; DRUG COMBINATIONS; HUMANS; KIDNEY TRANSPLANTATION; LUNG DISEASES, FUNGAL; MALE; MIDDLE AGED; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; ZYGOMYCOSIS;

EID: 17144418061     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2004.00076.x     Document Type: Article

References (23)

1. GONZALEZ CE, RINALDI MG, SUGAR AM. Zygomycosis. Infect Dis Clin North Am 2002: 16: 895-914.
2. PAGANO L, RICCI P, TONSO A, et al. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto). Br J Haematol 1997: 99: 331-336.
3. LEE FY, MOSSAD SB, ADAL KA. Pulmonary mucormycosis: the last 30 years. Arch Intern Med 1999: 159: 1301-1309.
4. WALSH TJ, FINBERG RW, ARNDT C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999: 340: 764-771.
5. PRENTICE HG, HANN IM, HERBRECHT R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997: 98: 711-718.
6. JOHNSON PC, WHEAT LJ, CLOUD GA, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 2002: 137: 105-109.
7. LUBER AD, MAA L, LAM M, GUGLIELMO BJ. Risk factors for amphotericin B-induced nephrotoxicity. J Antimicrob Chemother 1999: 43: 267-271.
8. BEKERSKY I, FIELDING RM, DRESSLER DE, LEE JW, BUELL DN, WALSH TJ. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother 2002: 46: 834-840.
9. BEKERSKY I, FIELDING RM, DRESSLER DE, LEE JW BUELL DN, WALSH TJ. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 2002: 46: 828-833.
10. ADLER-MOORE J, PROFFITT RT. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 2002: 49 (Suppl 1): 21-30.
11. TEDDER M, SPRATT JA, ANSTADT MP, HEGDE SS, TEDDER SD, LOWE JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg 1994: 57: 1044-1050.
12. KRENSKY AM, STROM TB, BLUESTONE JA. Immunomodulators: immunosuppressive agents, tolerogens, and immunostimulants. In: HARDMAN JG, LIMBIRD LE, GILMAN AG, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics (10th edn). New York: McGraw-Hill, 2001: 1463-1484.
13. BOECKH M, NICHOLS WG. Immunosuppressive effects of beta-herpesviruses. Herpes 2003: 10: 12-16.
14. WALSH TJ, PAPPAS P, WINSTON DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002: 346: 225-234.
15. ERIKSSON U, SEIFERT B, SCHAFFNER A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. Br Med J 2001: 322: 579-582.
16. FURRER K, SCHAFFNER A, VAVRICKA SR, HALTER J, IMHOF A, SCHANZ U. Nephrotoxicity of cyclosporine A and amphotericin B-deoxycholate as continuous infusion in allogenic stem cell transplantation. Swiss Med Wkly 2002: 132: 316-320.
17. SPEICH R, DUTLY A, NAEF R, RUSSI EW, WEDER W, BOEHLER A. Tolerability, safety and efficacy of conventional amphotericin B administered by 24-hour infusion to lung transplant recipients. Swiss Med Wkly 2002: 132: 455-458.
18. IMHOF A, WALTER RB, SCHAFFNER A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis 2003: 36: 943-951.
19. PELEG AY, WOODS ML. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. J Antimicrob Chemother 2004: 54: 803-808.
20. LEWIS RE, WIEDERHOLD NP. The solubility ceiling: a rationale for continuous infusion amphotericin B therapy? Clin Infect Dis 2003: 37: 871-872.
21. DANNAOUI E, MELETIADIS J, MOUTON JW, MEIS JF, VERWEIJ PE. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003: 51: 45-52.
22. SUN QN, FOTHERGILL AW, MCCARTHY DI, RINALDI MG, GRAYBILL JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002: 46: 1581-1582.
23. ESPINEL-INGROFF A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998: 36: 2950-2956.